Age, Biography and Wiki
Manish Doshi was born on 1968 in Anand, Gujarat, India, is a Manish Doshi is Indian. Discover Manish Doshi's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 56 years old?
Popular As |
N/A |
Occupation |
Founder and MD, Concept Medical Group |
Age |
56 years old |
Zodiac Sign |
N/A |
Born |
1968 |
Birthday |
|
Birthplace |
Anand, Gujarat, India |
Nationality |
|
We recommend you to check the complete list of Famous People born on .
He is a member of famous Founder with the age 56 years old group.
Manish Doshi Height, Weight & Measurements
At 56 years old, Manish Doshi height not available right now. We will update Manish Doshi's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
Physical Status |
Height |
Not Available |
Weight |
Not Available |
Body Measurements |
Not Available |
Eye Color |
Not Available |
Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
Family |
Parents |
Not Available |
Wife |
Not Available |
Sibling |
Not Available |
Children |
Not Available |
Manish Doshi Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Manish Doshi worth at the age of 56 years old? Manish Doshi’s income source is mostly from being a successful Founder. He is from . We have estimated Manish Doshi's net worth, money, salary, income, and assets.
Net Worth in 2024 |
$1 Million - $5 Million |
Salary in 2024 |
Under Review |
Net Worth in 2023 |
Pending |
Salary in 2023 |
Under Review |
House |
Not Available |
Cars |
Not Available |
Source of Income |
Founder |
Manish Doshi Social Network
Instagram |
|
Linkedin |
|
Twitter |
|
Facebook |
|
Wikipedia |
|
Imdb |
|
Timeline
Manish Doshi is an Indian entrepreneur who is the founder and managing director of Concept Medical, a medical devices company headquartered in Tampa, Florida and was the largest medical device exporter from India in 2022.
The company develops and manufactures drug-eluting stents and drug-coated balloon for cardiovascular treatment.
Under Manish's direction, Concept Medical developed MagicTouch, the world’s first sirolimus-drug coated balloon (SCB).
It is the only sirolimus-coated balloon globally approved with CE certification and extensive commercial usage in Europe, Asia and the Middle East.
In recognition of his pioneering work, he was awarded the Champions of Change, a national award given by the Government of India.
He also received an Honorary Doctorate and Marico Innovation Foundation's Innovation for India Award for his contributions to nanotechnology-based drug delivery for cardiovascular devices.
Manish was born in Anand, Gujarat, to parents Indulal Amritlal and Kokilaben Doshi.
His father, Indulal, worked as an account manager at Amul Dairy.
Manish studied at D N High School in Gamdi Vad, Anand, and earned a B.E. in Textile Technology from Maharaja Sayajirao University of Baroda.
Manish briefly worked in the textile industry at Mafatlal Industries in Navsari, then started his own import-export business supplying materials to the paint industry in Gujarat.
In 1998, angioplasties gained more popularity than bypass surgeries.
The spring-like components crucial for heart surgeries were not produced by any Indian company at the time.
Manish formed a team of engineers to improve the design of cardiovascular devices, with a focus on coronary stents in India.
The company became a pioneer in developing nanotechnology-based applications for drug delivery.
Manish started participating in clinical trials and conducting studies in the Netherlands following the receipt of CE approval for their stent.
During the 2000s, Manish faced a €25 million patent infringement lawsuit from Boston Scientific and Angiotech Pharmaceuticals.
Despite the legal loss, he only had to pay €1,400 since his product was still in the clinical trial phase, and commercialization in Europe was restricted.